doi: 10.1016/j.bmcl.2012.01.037.
Epub 2012 Jan 21.
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors
Affiliations
- PMID: 22306123
- DOI: 10.1016/j.bmcl.2012.01.037
Item in Clipboard
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors
Bioorg Med Chem Lett.
.
Abstract
A series of P1-substituted biaryl amprenavir derivatives was designed and synthesized. These compounds were evaluated for enzyme inhibition and antiviral activity in vitro. Several compounds showed highly efficient antiviral activity with EC(50) values down to 0.10nM, which are more potent than marketed HIV-1 protease inhibitors. Docking study indicated that 12c has similar binding mode to amprenavir with full occupancy in P1.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Oximinoarylsulfonamides as potent HIV protease inhibitors.Bioorg Med Chem Lett. 2005 May 2;15(9):2275-8. doi: 10.1016/j.bmcl.2005.03.008. Bioorg Med Chem Lett. 2005. PMID: 15837308
-
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.J Med Chem. 2005 May 19;48(10):3576-85. doi: 10.1021/jm050019i. J Med Chem. 2005. PMID: 15887965
-
Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.J Med Chem. 2013 Jul 11;56(13):5631-5. doi: 10.1021/jm400684f. Epub 2013 Jun 28. J Med Chem. 2013. PMID: 23772563 Free PMC article.
-
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".AIDS. 2008 Jan 2;22(1):165-7. doi: 10.1097/QAD.0b013e3282f2be42. AIDS. 2008. PMID: 18090413 Review. No abstract available.
-
HIV protease as a target for retrovirus vector-mediated gene therapy.Biochim Biophys Acta. 2000 Mar 7;1477(1-2):168-88. doi: 10.1016/s0167-4838(99)00272-1. Biochim Biophys Acta. 2000. PMID: 10708857 Review.
Cited by
-
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.J Med Chem. 2018 May 24;61(10):4561-4577. doi: 10.1021/acs.jmedchem.8b00298. Epub 2018 May 15. J Med Chem. 2018. PMID: 29763303 Free PMC article.
-
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.Eur J Med Chem. 2018 Dec 5;160:171-182. doi: 10.1016/j.ejmech.2018.09.046. Epub 2018 Sep 18. Eur J Med Chem. 2018. PMID: 30340140 Free PMC article.
-
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.Viruses. 2023 Aug 28;15(9):1826. doi: 10.3390/v15091826. Viruses. 2023. PMID: 37766233 Free PMC article. Review.
-
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. Epub 2020 Apr 29. J Med Chem. 2020. PMID: 32348139 Free PMC article.
-
BODIPY-based fluorescent liposomes with sesquiterpene lactone trilobolide.Beilstein J Org Chem. 2017 Jul 4;13:1316-1324. doi: 10.3762/bjoc.13.128. eCollection 2017. Beilstein J Org Chem. 2017. PMID: 28781697 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
